



# Supplementary Materials


A375 24 h







A375 48 h






A375 72 h











**Figure S1.** Viability of A375, C32 melanoma cells and dermal fibroblasts treated with compounds 1–37 or cisplatin for 24, 48 and 72 hours determined by a MTT assay. Data are presented as mean  $\pm$  SD from three independent experiments. \*  $p < 0.05$  compared to control group.









**Figure S2.** Viability of A375, C32 melanoma cells and dermal fibroblasts treated with compounds 1–37 or cisplatin for 24, 48 and 72 hours determined by a neutral red uptake assay. Data are presented as mean  $\pm$  SD from three independent experiments. \*  $p < 0.05$  compared to control group.


A375




C32




**Figure S3.** Quantitative analysis of western immunoblot images. Data are presented as mean  $\pm$  SD. \*  $p < 0.05$  compared to control group.




**Figure S4.** Quantitative analysis of immunofluorescence images. Data are presented as mean ± SD. \*  $p < 0.05$  compared to control group.




**Figure S5.** A375 cell line, RSK protein, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S6.** A375 cell line, pRSK protein, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S7.** A375 cell line, PARP and cPARP, first band—control, compounds (at 25 and 50 μM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S8.** A375 cell line, caspase 9, first band – control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S9.** A375 cell line, caspase 8, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S10.** A375 cell line, caspase 7, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S11.** A375 cell line, caspase 3, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S12.** A375 cell line, actin, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S13.** C32 cell line, RSK, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S14.** C32 cell line, pRSK, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S15.** C32 cell line, PARP and cPARP, first band—control, compounds (at 25 and 50 μM) in the order: 17, 6, 37, 1, 15, 16.




**Figure S16.** C32 cell line, caspase 9, first band – control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.



**Figure S17.** C32 cell line, caspase 7, first band – control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.



**Figure S18.** C32 cell line, caspase 3, first band – control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.



**Figure S19.** C32 cell line, actin, first band—control, compounds (at 25 and 50 uM) in the order: 17, 6, 37, 1, 15, 16.